サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631209

米国の組織診断市場規模、シェア、動向分析レポート：技術・製品別、用途別、セグメント別予測、2025年～2030年

U.S. Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology & Product (IHC, Primary & Special Staining), By Application (Breast Cancer, NSCLC), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
米国の組織診断市場規模、シェア、動向分析レポート：技術・製品別、用途別、セグメント別予測、2025年～2030年
出版日: 2024年12月06日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の組織診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、米国の組織診断市場規模は2030年までに44億米ドルに達し、2025～2030年のCAGRは8.3％を記録すると推定されています。

市場成長を補完する重要な要因としては、がん患者の継続的な増加、臓器移植と臓器提供の増加、米国における個別化医療とコンパニオン診断に対する受け入れの増加などが挙げられます。

解剖学的病理学セグメントはパラダイムシフトを目の当たりにしており、これは米国におけるがん罹患率の急激な伸びに起因しています。また、分子病理学と解剖学的病理学との着実な融合、がん検出のための新しい生検の急速な採用、デジタル技術の統合が、市場成長に共同でプラスの影響を与えると予想されます。

組織分析は、従来の分子技術では理解することが困難な重要な情報を記載しています。現在、コンパニオン診断検査は、製薬会社が自社製品の第一選択療法指定/承認を取得するために急速に採用されています。また、標的治療の効果が期待される患者コホートの同定に使用されることで、プレシジョン・メディシンの開発における組織診断の重要性が高まっています。

さらに、組織診断のセグメントは、蛍光その場ハイブリダイゼーション（FISH）、免疫組織化学（IHC）、免疫蛍光（IF）、比較ゲノムハイブリダイゼーション、次世代シーケンシング（NGS）などのアップグレード技術の採用よって徐々に進化しています。主要企業は、新規バイオマーカーの同定と先進的がん診断のためのアッセイ開発に注力しています。さらに、各社は最新の病理学的ソリューションの採用率を高めるため、バイオマーカー病理医のトレーニングプログラムを実施しています。

米国組織診断市場レポートハイライト

  • 技術・製品別では、免疫組織化学セグメントが2024年に27.74%の最大売上シェアで市場をリードしています。
  • 用途別では、乳がんセグメントが2024年に50.45%の最大売上シェアで市場をリードしています。組織診断は、患者の乳がんを評価する上で重要な役割を果たしています。
  • 最終用途別では、病院セグメントが2024年に37.82％の最大売上シェアで市場をリードしました。病院・クリニックにおける組織診断システムとサービスの利用は年々増加しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の組織診断市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 米国の組織診断市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の組織診断市場：技術・製品別、推定・動向分析

  • セグメントダッシュボード
  • 米国の組織診断市場：技術・製品の変動分析
  • 米国の組織診断市場：技術・製品の展望
  • 2018～2030年の市場規模と予測と動向分析
  • 免疫組織化学
    • 機器
    • 消耗品
  • in situーハイブリダイゼーション
    • 機器
    • 消耗品
    • ソフトウェア
  • 一次染色と特殊染色
    • H&E染色
    • 特殊染色
  • デジタル病理学とワークフロー
    • スライド全体のイメージング
    • 画像分析情報学
    • 情報管理システムの保管と通信
  • 解剖病理学
    • 機器
    • 消耗品

第5章 米国の組織診断市場：用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国の組織診断市場：用途の変動分析
  • 米国の組織診断市場：用途の展望
  • 2018～2030年の市場規模と予測と動向分析
  • 乳がん
  • 非小細胞肺がん
  • 前立腺がん
  • 胃がん
  • その他のがん

第6章 米国の組織診断市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国の組織診断市場：最終用途変動分析
  • 最終用途別米国組織診断市場展望
  • 2018～2030年の市場規模と予測と動向分析
  • 病院
  • ラボ
  • 製薬団体
  • 最高経営責任者

第7章 競合情勢

  • 市場参入企業の分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 主要企業プロファイル
    • Merck KGaA
    • Thermo Fisher Scientific, Inc
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher
    • bioMerieux SA
    • QIAGEN
    • Becton, Dickinson &Company（BD）
    • Agilent Technologies, Inc
    • General Electric Company
    • BioGenex
    • Cell Signaling Technology, Inc
    • Bio SB
    • DiaGenic ASA
    • Sakura Finetek Japan Co., Ltd
    • Abcam plc
    • Enzo Life Sciences, Inc
    • VITRO SA（Master Diagnostica）
    • TissueGnostics GmbH
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Tissue Diagnostics market, by Technology & Product, 2018 - 2030 (USD Million)
  • Table 4 U.S. Tissue Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 5 U.S. Tissue Diagnostics market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. tissue diagnostics market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 U.S. tissue diagnostics market, technology & product outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 12 U.S. tissue diagnostics market, application outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 13 U.S. tissue diagnostics market, end use outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 14 Immunohistochemistry market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Instruments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Slide Staining Systems market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Tissue Microarrays market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Tissue Processing Systems market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Slide Scanners market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Other Products market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Consumables market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Antibodies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Kits market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 In situ Hybridization market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Instruments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Consumables market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Software market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Primary & Special Staining market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 H&E Staining market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Special Staining market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Digital Pathology and Workflow market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Whole Slide Imaging market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Image Analysis Informatics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Information Management System Storage & Communication market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Anatomic Pathology market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Instruments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Microtomes &Cryostat Microtomes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Tissue Processors market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Automatic Strainers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Other Products market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Consumables market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Reagents & Antibodies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Probes & Kits market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Breast Cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Non-Small Cell Lung Cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Prostate Cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Gastric Cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Other Cancers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Research Laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Pharmaceutical Organizations market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 CRO market revenue estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68038-270-9

U.S. Tissue Diagnostics Market Growth & Trends:

The U.S. tissue diagnostics market size is estimated to reach USD 4.40 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pivotal factors supplementing the market growth include continuous rise in the cases of cancer, growth in organ transplantation & donation, and increased acceptance toward personalized medicine & companion diagnostics in the U.S. Increase in the number of research activities targeted toward the development of novel tissue diagnostics solutions is also expected to drive the market.

The field of anatomic pathology has witnessed a paradigm shift, which can be attributed to the exponential growth in cancer incidence in the U.S., thereby expanding the clinical pathology industry. Also, steady convergence of molecular pathology with anatomic pathology, steep adoption of novel biopsies for cancer detection, and integration of digital technologies is expected to collaboratively make a positive impact on market growth.

Tissue analysis provides significant information, which is difficult to understand using conventional molecular techniques. Currently, companion diagnostic tests are rapidly being adopted by pharmaceutical companies for obtaining first-line therapy designations/approvals for their products. In addition, their use in the identification of patient cohorts, which are likely to benefit from targeted therapeutics, has increased the significance of tissue diagnostics in the development of precision medicine.

In addition, the field of tissue diagnostics has witnessed gradual evolution with the introduction of upgraded technologies, including Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Immunofluorescence (IF), comparative genomic hybridization, and Next-Generation Sequencing (NGS). Key players are focused on identifying novel biomarkers and developing assays for advanced cancer diagnosis. Furthermore, companies are conducting biomarker pathologist training programs to boost the adoption rate of modern pathological solutions.

U.S. Tissue Diagnostics Market Report Highlights:

  • Based on technology & product, the immunohistochemistry segment led the market with the largest revenue share of 27.74% in 2024.
  • Based on application, the breast cancer segment led the market with the largest revenue share of 50.45% in 2024. Tissue diagnostics play a vital role in assessing breast cancer in patients.
  • Based on end use, the hospitals segment led the market with the largest revenue share of 37.82% in 2024. The usage of tissue diagnostic systems and services in hospitals & clinics has increased over the years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology & Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. U.S. Tissue Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emerging solutions pertaining to digital tissue diagnostics
      • 3.2.1.2. Advancements in imaging techniques and increasing affordability of diagnostics
      • 3.2.1.3. Growth of personalized therapeutics and diagnostics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of non-value-based reimbursement policy and high costs associated with usage of tissue diagnosis
  • 3.3. U.S. Tissue Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. U.S. Tissue Diagnostics Market: Technology & Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Tissue Diagnostics Market: Technology & Product Movement Analysis
  • 4.3. U.S. Tissue Diagnostics Market by Technology & Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Immunohistochemistry
    • 4.5.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Instruments
      • 4.5.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.2. Slide Staining Systems
        • 4.5.2.2.1. Slide Staining Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.3. Tissue Microarrays
        • 4.5.2.3.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.4. Tissue Processing Systems
        • 4.5.2.4.1. Tissue Processing Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.5. Slide Scanners
        • 4.5.2.5.1. Slide Scanners Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.2.6. Other Products
        • 4.5.2.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Consumables
      • 4.5.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. Reagents
        • 4.5.3.2.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.3. Antibodies
        • 4.5.3.3.1. Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. In situ Hybridization
    • 4.6.1. In situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Instruments
      • 4.6.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Consumables
      • 4.6.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Software
      • 4.6.4.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Primary & Special Staining
    • 4.7.1. Primary & Special Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. H&E Staining
      • 4.7.2.1. H&E Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. Special Staining
      • 4.7.3.1. Special Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Digital Pathology and Workflow
    • 4.8.1. Digital Pathology and Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.2. Whole Slide Imaging
      • 4.8.2.1. Whole Slide Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.3. Image Analysis Informatics
      • 4.8.3.1. Image Analysis Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.4. Information Management System Storage & Communication
      • 4.8.4.1. Information Management System Storage & Communication Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Anatomic Pathology
    • 4.9.1. Anatomic Pathology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.2. Instruments
      • 4.9.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.2.2. Microtomes & Cryostat Microtomes
        • 4.9.2.2.1. Microtomes & Cryostat Microtomes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.2.3. Tissue Processors
        • 4.9.2.3.1. Tissue Processors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.2.4. Automatic Strainers
        • 4.9.2.4.1. Automatic Strainers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.2.5. Other Products
        • 4.9.2.5.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.3. Consumables
      • 4.9.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.3.2. Reagents & Antibodies
        • 4.9.3.2.1. Reagents & Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.3.3. Probes & Kits
        • 4.9.3.3.1. Probes & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.9.3.4. Others
        • 4.9.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Tissue Diagnostics Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Tissue Diagnostics Market: Application Movement Analysis
  • 5.3. U.S. Tissue Diagnostics Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Breast Cancer
    • 5.5.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-Small Cell Lung Cancer
    • 5.6.1. Non-Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Prostate Cancer
    • 5.7.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Gastric Cancer
    • 5.8.1. Gastric Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Cancers
    • 5.9.1. Other Cancers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Tissue Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Tissue Diagnostics Market: End Use Movement Analysis
  • 6.3. U.S. Tissue Diagnostics Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Research Laboratories
    • 6.6.1. Research Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pharmaceutical Organizations
    • 6.7.1. Pharmaceutical Organizations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. CRO
    • 6.8.1. CRO Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Merck KGaA
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Thermo Fisher Scientific, Inc
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Abbott Laboratories
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Siemens Healthineers AG
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Danaher
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. bioMerieux SA
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. QIAGEN
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Becton, Dickinson & Company (BD)
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Agilent Technologies, Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. General Electric Company
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. BioGenex
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. Cell Signaling Technology, Inc
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. Bio SB
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives
    • 7.4.15. DiaGenic ASA
      • 7.4.15.1. Company overview
      • 7.4.15.2. Financial performance
      • 7.4.15.3. Product benchmarking
      • 7.4.15.4. Strategic initiatives
    • 7.4.16. Sakura Finetek Japan Co., Ltd
      • 7.4.16.1. Company overview
      • 7.4.16.2. Financial performance
      • 7.4.16.3. Product benchmarking
      • 7.4.16.4. Strategic initiatives
    • 7.4.17. Abcam plc
      • 7.4.17.1. Company overview
      • 7.4.17.2. Financial performance
      • 7.4.17.3. Product benchmarking
      • 7.4.17.4. Strategic initiatives
    • 7.4.18. Enzo Life Sciences, Inc
      • 7.4.18.1. Company overview
      • 7.4.18.2. Financial performance
      • 7.4.18.3. Product benchmarking
      • 7.4.18.4. Strategic initiatives
    • 7.4.19. VITRO SA (Master Diagnostica)
      • 7.4.19.1. Company overview
      • 7.4.19.2. Financial performance
      • 7.4.19.3. Product benchmarking
      • 7.4.19.4. Strategic initiatives
    • 7.4.20. TissueGnostics GmbH
      • 7.4.20.1. Company overview
      • 7.4.20.2. Financial performance
      • 7.4.20.3. Product benchmarking
      • 7.4.20.4. Strategic initiatives